...the research facility, which focused on lower urinary tract disorders, from Dynogen Pharmaceuticals Inc. in March 2006. Dynogen...

...testing for gastroesophageal reflux disease (GERD). Mitsubishi granted Dynogen Pharmaceuticals Inc. rights to the product in 2004. Dynogen...
...filed Chapter 7 bankruptcy in 2009. During the same year, Care Capital acquired most of Dynogen's...

...Cambridge, Mass. Business: Metabolic, Inflammation Hired: Lee Brettman as CMO, formerly president and CEO of Dynogen Pharmaceuticals Inc. WIR...

...Switzerland Business: Genitourinary, Endocrine Hired: Suhail Nurbhai as CMO, formerly VP of clinical development at Dynogen Pharmaceuticals Inc. WIR...

...Pharmaceuticals Inc. , Waltham, Mass. Business: Gastrointestinal Dynogen filed for Chapter 7 bankruptcy. Last year, Dynogen...
...acquisition by special purpose acquisition company Apex Bioventures Acquisition Corp. (NYSE-A:PEX, Hillsborough, Calif.) fell through. Dynogen's...

...April, the SPAC called it quits on a reverse merger with gastrointestinal and genitourinary company Dynogen...

...of placebo patients. Data were presented at the Digestive Disease Week meeting in San Diego. Dynogen...
...has rights to DDP225 from Mitsubishi under a 2003 deal (see BioCentury, Jan. 5, 2004). Dynogen Pharmaceuticals Inc....

...This year, Dynogen will begin a double-blind, placebo-controlled, North American Phase llb trial of oral DDP225...
...oral DDP225. The company has rights to DDP225 from Mitsubishi (see BioCentury, Jan. 5, 2004). Dynogen Pharmaceuticals Inc....

...purpose acquisition company Apex and Dynogen terminated a deal under which Apex would have acquired Dynogen...
...conditions. Dynogen said it is planning a private financing this year (see BioCentury, Feb. 11). Dynogen Pharmaceuticals Inc....

...of the combined company. Calling it quits Citing difficult market conditions, gastrointestinal and genitourinary company Dynogen...
...and special purpose acquisition company Apex Bioventures (AMEX:PEX) called off their reverse merger last week. Dynogen...
...February. The terms called for the acquisition to be for $98 million in stock, with Dynogen...